Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer-Reference-Cited by-同舟云学术

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

Published:2018-02 Issue:2 Volume:73 Page:149-152
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Szabados Bernadett,van Dijk Nick,Tang Yen Zhi,van der Heijden Michiel S.,Wimalasingham Akhila,Gomez de Liano Alfonso,Chowdhury Simon,Hughes Simon,Rudman Sarah,Linch Mark,Powles Thomas

Publisher

Elsevier BV

Subject

Urology

Reference8 articles.

1. Bladder cancer;Kaufman;Lancet,2009

2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;Maase von der;J Clin Oncol,2005

3. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy;Galsky;Lancet Oncol,2011

4. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium;Sonpavde;Lancet Oncol,2010

5. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now;Bellmunt;Cancer Treat Rev,2017

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study;ESMO Open;2024-09

4. Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases;Journal of Gastroenterology;2024-08-17

5. The evolving treatment landscape of metastatic urothelial cancer;Nature Reviews Urology;2024-05-03